Abstracts tagged "Patient reported outcomes"

Abstract Number: 1652 • ACR Convergence 2021
Symptom Burden in Anti-citrullinated Protein Antibody Positive Individuals At-risk for Rheumatoid Arthritis Is Changing over Time and Comparable to Patients with Early Rheumatoid Arthritis
Paul Studenic¹, Alexandra Circiumaru², Daniel Aletaha³, Katerina Chatzidionysiou⁴, Anca Catrina⁵ and Aase Haj Hensvold⁶, ¹Karolinska Institute; & Medical University of Vienna, Stockholm, Sweden, ²Division for Rheumatology, Karolinska Institutet; Center for Rheumatology, Academic Specialist Center, Stockholm Region, Stockholm, Sweden, ³Medical University Vienna, Vienna, Austria, ⁴Karolinska Institute, Division of Rheumatology; & Karolinska University Hospital, Rheumatology Unit, Stockholm, Sweden, ⁵Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ⁶Karolinska Institutet, Division for Rheumatology; & Center for Rheumatology, Academic Specialist Center, Stockholm Region, Stockholm, Sweden
Background/Purpose: Symptom burden in individuals at risk for developing rheumatoid arthritis (RA) - positive for anti-citrullinated peptide antibodies (ACPA) and musculoskeletal complaints - has not…
Abstract Number: 0124 • ACR Convergence 2021
Nurse-supported Web-based Cognitive Behavioral Therapy for Chronic Musculoskeletal Pain: An Effectiveness Trial
Rami Diab¹, Rebecca Bomar², Christina Rinaldi², Claudia Campos², Sebastian Kaplan² and Dennis Ang³, ¹Wake Forest Baptist Health/Wake Forest School of Medicine, Winston-Salem, NC, ²Wake Forest School of Medicine / Wake Forest University Baptist Medical Center, Winston-Salem, NC, ³Wake Forest School of Medicine, Winston-Salem, NC
Background/Purpose: Pain accounts for greater than 40% of all symptom-related outpatient visits totaling over 100 million outpatient encounters worth hundreds of billions of dollars annually…
Abstract Number: 0401 • ACR Convergence 2021
Item Reduction for the Assessment of Systemic Sclerosis-associated RAynaud’s Phenomenon (ASRAP) Questionnaire Using Data from the International Multicentre ASRAP Validation Study
John Pauling¹, Lan Yu², Christopher Denton³, Tracy Frech⁴, Ariane Herrick⁵, Laura Hummers⁶, Lesley Ann Saketkoo⁷, Ami Shah⁸, Dinesh Khanna⁹ and Robyn Domsic², ¹Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²University of Pittsburgh, Pittsburgh, PA, ³University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom, ⁴University of Utah, Salt Lake City, UT, ⁵University of Manchester, Salford, United Kingdom, ⁶Johns Hopkins Univerisity, Baltimore, MD, ⁷University Medical Center - Comprehensive Pulmonary Hypertension Center, New Orleans, LA, ⁸Johns Hopkins Rheumatology, Baltimore, MD, ⁹University of Michigan, Ann Arbor, MI
Background/Purpose: The Assessment of Systemic sclerosis-associated RAynaud’s Phenomenon (ASRAP) questionnaire is a novel patient-reported outcome (PRO) instrument devised to assess the severity and impact of…
Abstract Number: 0741 • ACR Convergence 2021
Assessing the Relationship of Patient Global Assessment of Disease Activity and Health Related Quality of Life by SF-36 with Other Patient-Reported Outcomes in Rheumatoid Arthritis: Post Hoc Analyses of Data from Phase 3 Trials of Baricitinib
Vibeke Strand¹, Anthony Sebba², Savannah Scardo³, Amanda Quebe⁴, Liliana Zaremba-Pechmann⁵ and Peter C Taylor⁶, ¹Stanford University, Portola Valley, CA, ²Division of Rheumatology, University of South Florida, Tampa, FL, ³Eli Lilly and Company, Indianapolis, IN, ⁴Eli Lilly and Company, Indanapolis, IN, ⁵HaaPACS, Schriesheim, Germany, ⁶University of Oxford, Oxford, United Kingdom
Background/Purpose: Improvements in patient-reported outcomes (PROs) were demonstrated in randomized controlled trials (RCTs) of baricitinib (BARI), an oral Janus kinase (JAK)1/JAK2 inhibitor, for the treatment…
Abstract Number: 0763 • ACR Convergence 2021
What Does the Patient Well-Being Vas Tell Us When the Physician Global Assessmentscore Is Zero? Analysis of a Large Multinational Dataset
Francesca Ridella¹, Roberta Naddei², Maddalena Spelta², Cristina N. Herrera³, Clara Malagon⁴, Olga Arguedas⁵, Amparo Ibanez Estrella⁶, Nicola Ruperto⁷, Angelo Ravelli⁸ and Alessandro Consolaro⁹, ¹Università degli Studi di Genova Genoa, Italy, Genova, Italy, ²Istituto Giannina Gaslini, Genova, Italy, ³Hospital de Ninos Roberto Gilbert Elizalde, Rheumatology, Guayaquil, Ecuador, Paediatric Rheumatology International Trials Organisation (PRINTO), Guayaquil, Ecuador, ⁴Hospital Universitario Simon Bolivar, Clinica infantil Colsubsidio, Facultad de Medicina, Post Grado Reumatologia Pediatrica, Universidad El Bosque, Bogota, Colombia, Paediatric Rheumatology International Trials Organisation (PRINTO), Bogotà, Colombia, ⁵Hospital Nacional de Ninos Dr Carlos Saenz Herrera, Servicio de Immunologia y Reumatologia pediatrica, San Josè, Costa Rica, Paediatric Rheumatology International Trials Organisation (PRINTO), San Josè, Costa Rica, ⁶National Institute Salud del Nino, Rheumatology Service, Brena, Lima, Peru, Paediatric Rheumatology International Trials Organisation (PRINTO), Lima, Peru, ⁷Istituto Giannina Gaslini, Paediatric Rheumatology International Trials Organisation (PRINTO), Genova, Italy, ⁸Istituto Giannina Gaslini, Genoa, Italy, ⁹Istituto Giannina Gaslini, Università degli Studi di Genova, Genova, Italy
Background/Purpose: Parent- and child-reported outcomes (PCROs) reflect the parent and child perception of rheumatic disease course and effectiveness of therapeutic interventions. Among PCROs for the…
Abstract Number: 0869 • ACR Convergence 2021
Comparison of Two Frailty Definitions in Women with Systemic Lupus Erythematosus
Sarah Lieber¹, Musarrat Nahid², Alexandra Legge³, Mangala Rajan², Robyn Lipschultz¹, Myriam Lin¹ and Lisa Mandl¹, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY, ³Dalhousie University, Halifax, NS, Canada
Background/Purpose: Frailty is a novel risk factor for adverse health outcomes in systemic lupus erythematosus (SLE). Multiple definitions of frailty, including the Fried definition (FD),…
Abstract Number: 1223 • ACR Convergence 2021
A Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic or Biologic Disease-Modifying Therapies: 6-Month Effectiveness and Patient Reported Outcome Data from the European Cohort
Gerd Burmester¹, Bruno Fautrel², Rieke Alten³, Marco Matucci-Cerinic⁴, Jean hugues Salmon⁵, Thorsten Holzkaemper⁶, Inmaculada de la Torre⁷, Pedro Lopez-Romero⁸, Walid Fakhouri⁸ and Anja Gentzel-Jorczyk⁸, ¹Charité University Medicine Berlin, Berlin, Germany, ²Pitié Salpêtrière Hospital, APHP, Sorbonne Université, Paris, France, ³Schlosspark-Klinik University, Berlin, Germany, ⁴University of Florence, Florence, Italy, ⁵Rheumatology, CHU Maison blanche, Reims, Reims, France, ⁶Eli Lilly and Company, Bad Homburg, Germany, ⁷Eli Lilly and Company, Alcobendas, Spain, ⁸Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Baricitinib (BARI) is a JAK1/2 inhibitor approved for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) and the treatment of…
Abstract Number: 1380 • ACR Convergence 2021
Quality of Life in Patients with Scleroderma Associated Calcinosis Cutis: A Cross-Sectional Study
Aditi Patel¹, Mehnaj Grewal², Robert Butler² and Soumya Chatterjee³, ¹Cleveland Clinic, Cleveland Heights, OH, ²Cleveland Clinic, Cleveland, OH, ³Cleveland Clinic, Richmond Heights, OH
Background/Purpose: Calcinosis cutis (CC) can commonly affect patients with systemic sclerosis (SSc), which is often painful, resulting in functional impairment and morbidity. A radiographic scoring…
Abstract Number: 1672 • ACR Convergence 2021
Many Better, Many Worse: Mean PROMIS-29 Scores Mask Significant Shifts During COVID-19 in RA
Susan Bartlett¹, Dana DiRenzo², Michelle Jones³ and Clifton Bingham², ¹McGill University, Montréal, QC, Canada, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins Medicine, Baltimore, MD
Background/Purpose: Rheumatic diseases (RD) are chronic conditions that require potent immunosuppressants to control systemic inflammation. Fears associated with increased vulnerability from being on immunosuppressants plus…
Abstract Number: 0145 • ACR Convergence 2021
Rheumatology Provider Perspectives on Using Patient-Reported Outcomes in Clinical Care
Yomei Shaw¹, Neda Kortam², Adam Chalak², Yujia Li², Faith Reger², Vivek Nagaraja² and Dinesh Khanna², ¹University of Michigan, East Lansing, MI, ²University of Michigan, Ann Arbor, MI
Background/Purpose: Patient-reported outcomes (PROs) are surveys completed by patients to provide measurements of health, quality of life, symptoms, and functional status. PROs are useful for…
Abstract Number: 0402 • ACR Convergence 2021
What Is the Patient’s Perspective on Symptoms Experience in Limited Cutaneous Systemic Sclerosis?
Alain Lescoat¹, Susan Murphy², Yen Chen³, Nadia Vann¹, David Cella⁴ and Dinesh Khanna³, ¹Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ²University of Michigan, Grosse Ile, MI, ³University of Michigan, Ann Arbor, MI, ⁴Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Limited cutaneous SSc (lcSSc) affects approximately 60-70% of SSc patients but drug development and therapeutic research has largely focused on the more severe diffuse…
Abstract Number: 0743 • ACR Convergence 2021
Pain Interference, Fatigue, Physical Function as Outcome Measures in Adult Myositis: Updates on the Validation Process by the OMERACT Myositis Working Group
Dana DiRenzo¹, Ingrid de Groot², Helene Alexanderson³, Clifton Bingham¹, Ingrid E Lundberg⁴, Merrilee Needham⁵, Jin Kyun Park⁶, Malin Regardt³, Catherine Sarver⁷, Didem Saygin⁸, Yeong-Wook Song⁶, Lara Maxwell⁹, Dorcas Beaton¹⁰, Lisa Christopher-Stine¹ and Christopher Mecoli¹¹, ¹Johns Hopkins University, Baltimore, MD, ²patient research partner, Rotterdam, Netherlands, ³Karolinska Institutet, Stockholm, Sweden, ⁴Karolinska Institutet, Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, Stockholm, Sweden, ⁵Murdoch University, Perth, Australia, ⁶Seoul National University Hospital, Seoul, Republic of Korea, ⁷patient research partner, Baltimore, MD, ⁸University of Chicago, Chicago, IL, ⁹University of Ottawa, Ottawa, ON, Canada, ¹⁰Institute for Work & Health, Toronto, ON, Canada, ¹¹Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: People living with idiopathic inflammatory myositis (IIM) suffer impairments in health-related quality of life (HRQL), especially in the domains of pain interference, fatigue, and…
Abstract Number: 0766 • ACR Convergence 2021
Baseline Characteristics and Patient Reported Outcomes from a Juvenile Dermatomyositis Registry Inception Cohort
Jessica Neely¹, Kaveh Ardalan², Adam Huber³ and Susan Kim⁴, ¹University of California San Francisco, San Francisco, CA, ²Duke University Medical Center, Durham, NC, ³Dalhousie University, Halifax, NS, Canada, ⁴UCSF Benioff Children's Hospital, San Francisco, CA
Background/Purpose: Juvenile dermatomyositis (JDM), the most common inflammatory myopathy of children, is rare, with an estimated incidence of 2-4 in 1 million children. Given the…
Abstract Number: 0909 • ACR Convergence 2021
How Does Gender Affect Secukinumab Treatment Outcomes and Retention Rates in Patients with Ankylosing Spondylitis? – Real World Data from a German Observational Study
Uta Kiltz¹, Jan Brandt-Jrgens², Peter Kästner³, Elke Riechers⁴, Daniel Peterlik⁵ and Hans-Peter Tony⁶, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Rheumatologische Schwerpunktpraxis, Berlin, Germany, ³Ambulantes Rheumazentrum Erfurt, Erfurt, Germany, ⁴Department for Rheumatology and Immunology, Hannover Medical University, Hannover, ⁵Novartis Pharma GmbH, Nürnberg, Germany, ⁶Universitätsklinikum Würzburg, Wuerzburg, Germany
Background/Purpose: Current studies suggest that the phenotype of spondyloarthritis differs between genders and that this may influence the subsequent diagnostic approach and therapeutic decisions1. The…
Abstract Number: 1233 • ACR Convergence 2021
Physician and Patient Reported Effectiveness Outcomes Are Similar in Tofacitinib and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from a Rheumatoid Arthritis Registry in Canada
Mohammad Movahedi¹, Angela Cesta², Xiuying Li², Edward Keystone³ and Claire Bombardier⁴, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Toronto General Hospital Research Institute, UHN, Toronto, ON, Canada, ³Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁴University of Toronto - Toronto, Toronto, ON, Canada
Background/Purpose: Tofacitinib (TOFA) is an oral, small molecule drug used for rheumatoid arthritis (RA) treatment as an alternative option to biologic disease modifying antirheumatic drugs…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].